Holdings A/S Novo Sells 10,000 Shares of KalVista Pharmaceuticals, Inc. (KALV) Stock
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Holdings A/S Novo sold 10,000 shares of the firm’s stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $8.05, for a total transaction of $80,500.00. Following the completion of the sale, the insider now owns 2,876,027 shares of the company’s stock, valued at $23,152,017.35. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Holdings A/S Novo also recently made the following trade(s):
- On Wednesday, September 13th, Holdings A/S Novo sold 25,900 shares of KalVista Pharmaceuticals stock. The shares were sold at an average price of $8.02, for a total transaction of $207,718.00.
- On Friday, September 15th, Holdings A/S Novo sold 176,647 shares of KalVista Pharmaceuticals stock. The shares were sold at an average price of $7.21, for a total transaction of $1,273,624.87.
Shares of KalVista Pharmaceuticals, Inc. (NASDAQ KALV) traded down 13.11% during midday trading on Friday, reaching $6.96. 162,624 shares of the company’s stock traded hands. KalVista Pharmaceuticals, Inc. has a 12 month low of $6.09 and a 12 month high of $10.65. The firm’s market cap is $67.60 million. The stock has a 50-day moving average price of $8.20 and a 200 day moving average price of $7.83.
KalVista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Thursday, September 14th. The specialty pharmaceutical company reported ($0.51) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.59) by $0.08. KalVista Pharmaceuticals had a negative net margin of 5,863.31% and a negative return on equity of 63.41%. The firm had revenue of $0.10 million during the quarter. Equities research analysts predict that KalVista Pharmaceuticals, Inc. will post ($2.94) earnings per share for the current year.
An institutional investor recently bought a new position in KalVista Pharmaceuticals stock. Eventide Asset Management LLC bought a new stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 98,100 shares of the specialty pharmaceutical company’s stock, valued at approximately $766,000. Eventide Asset Management LLC owned 1.01% of KalVista Pharmaceuticals as of its most recent SEC filing. Institutional investors own 75.66% of the company’s stock.
KALV has been the subject of several recent analyst reports. BTIG Research initiated coverage on shares of KalVista Pharmaceuticals in a research note on Thursday, August 31st. They issued a “buy” rating and a $18.00 target price for the company. ValuEngine upgraded shares of KalVista Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 2nd.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, formerly Carbylan Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME).
Receive News & Ratings for KalVista Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.